Opko Health Inc. (OPK) Dividend History

Opko Health Inc. is a healthcare company specializing in the development of innovative diagnostics and pharmaceuticals. Founded in 2007, the company focuses on personalized medicine, providing diagnostic tests and treatments in areas such as oncology, neurology, and infectious diseases. Its portfolio includes bio-pharmaceutical products, laboratory services, and consumer health products aimed at improving patient outcomes through targeted healthcare solutions.

4400 Biscayne Blvd., Miami, FL, 33137
Phone: 305-575-4181
Website: https://www.opko.com

Dividend History

Opko Health Inc. currently does not pay dividends

Company News

Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 | DelveInsight

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases, technological advancements, and growing awareness of digital health solutions. North America is expected to dominate the market during the forecast period.

GlobeNewswire Inc.

Featured Companies: ATR
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide

The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

GlobeNewswire Inc.

Featured Companies: ADPT AMGN BIO BIO.B BMY DGX EXAS GH GILD ILMN LH MDXH MYGN NEO NTRA TECH VCYT
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

OPKO Health and Entera Bio have entered into a collaboration agreement to advance an oral GLP-1/Glucagon dual agonist tablet into clinical trials for the treatment of obesity and metabolic disorders.

GlobeNewswire Inc.

Featured Companies: ENTX
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

ModeX Therapeutics, an OPKO Health company, has been awarded additional funding from BARDA to develop multispecific antibodies for SARS-CoV-2 and influenza. The funding will support preclinical and Phase 1 trials for these programs, which are based on ModeX's proprietary MSTAR technology.

GlobeNewswire Inc.
Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024

This report analyzes the global market for laboratory-developed tests (LDTs), including the impact of new FDA regulations introduced in 2024. It covers the LDT services market and the market for LDT products sold to clinical laboratories, with a focus on key segments like infectious disease and oncology.

GlobeNewswire Inc.

Featured Companies: A ADPT BDSX BRKR CDNA DGX GH ILMN LH MDXH MYGN NEO NTRA PACB PKI QGEN TMO WAT

Dividend data last updated 06/07/2025 12:07:30 UTC